Navigation Links
RAD001 Phase II Trial Results Positive in Patients with Advanced Gastric Cancer After Failure of One or More Prior Treatments
Date:1/13/2009

ence Interval: 50 - 91 days), with 29.6% of patients estimated to still be progression-free at four months. Median overall survival was not attained at the time of evaluation.

The most commonly reported adverse events (all grades; >10% patients) in the study included, stomatitis, anorexia, fatigue, rash, nausea, edema peripheral, thrombocytopenia, diarrhea, pruritus, anemia, dysgeusia, vomiting, pyrexia, pneumonitis, constipation and insomnia. Serious adverse events (grade 3 or 4; >3% of patients) included anemia, hyponatremia, raised liver function, fatigue, stomatitis, anorexia, hyperglycemia, hypophosphatemia, ileus and lymphopenia.

About RAD001

RAD001, an oral once-daily inhibitor of mTOR, is an investigational drug being studied in multiple tumor types. In cancer cells, RAD001 provides daily inhibition of mTOR, a protein that acts as a central regulator of tumor cell division, cell metabolism and blood vessel growth.

RAD001 is being studied in multiple cancer types including advanced kidney, breast and neuroendocrine tumors and lymphoma. Currently, RAD001 is under regulatory review in the US and Europe for the treatment of advanced renal cell carcinoma.

The safety and efficacy profile of RAD001 has not yet been established in oncology and there is no guarantee that RAD001 will become commercially available for oncology indications. The active ingredient in RAD001 is everolimus, which is available in different dosage strengths under the trade name Certican(R) for the prevention of organ rejection in heart and kidney transplant recipients. Certican was first approved in the EU in 2003. Certican is not approved in the US.

Disclaimer

The foregoing release contains forward-looking statements that can be identified by terminology such as "promising," "will," "potential," "may," "committed," "exploring," "believed," "e
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Everolimus (RAD001) Significantly Extends Progression-Free Survival in Advanced Kidney Cancer Patients After Failure of Other Targeted Therapy
2. RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer
3. Early Data Presented at ASCO Show Potential of RAD001 to Enhance Efficacy of, and Overcome Resistance to, Breast Cancer Treatments
4. RAD001 Granted Priority Review in the US Based on Potential to Fill Unmet Medical Need in Patients With Advanced Kidney Cancer
5. RAD001 Combined with Sandostatin LAR(R) Depot and as Monotherapy Controls Growth of Rare Pancreatic Neuroendocrine Tumors
6. Latest RAD001 Study Results Show Further Increase in Time Without Tumor Growth in Patients With Advanced Kidney Cancer
7. RAD001 Shows Potential to Reverse Resistance to Herceptin(R)* in Metastatic Breast Cancer Patients, Leading to Phase III Trial
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
10. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
11. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced that ... 31, 2014 on March 9, 2015. The Company also plans to ... 12, 2015, at 5:00 pm ET. The call will be hosted ...   , , , LIVE CALL:  , , , ... , , , , , ...
(Date:3/1/2015)... , March 1, 2015  An innovative ... chronic migraine sufferers sustained relief of their headaches, ... Society of Interventional Radiology ,s Annual Scientific ... the State University New York Empire State College ... intranasal sphenopalatine ganglion (SPG) blocks to give patients ...
(Date:2/27/2015)... Feb. 27, 2015 Pharmaceutical and biotech marketers ... products for the same indication. This can be a ... to prevent one of their brands from gaining market ... to recent research by benchmarking firm, Best Practices, LLC, ... brands rather than together as part of a franchise. ...
Breaking Medicine Technology:ImmunoCellular Therapeutics to Report 2014 Financial Results on March 9, 2015; a Business Update Conference Call and Webcast is Scheduled for March 12, 2015 2Image-guided treatment shown to break the migraine cycle 2Image-guided treatment shown to break the migraine cycle 3Image-guided treatment shown to break the migraine cycle 4New Report Details How to Expand a Pharmaceutical Product Portfolio without Cannibalizing an Established Brand 2
... Scientific Corporation (NYSE: BSX ) today announced ... 60th Annual Scientific Session of the American College of ... "Twelve-month results from the PLATINUM Workhorse clinical trial ... Everolimus-Eluting Platinum Chromium (PtCr) Stent as compared to our ...
... DIEGO, March 29, 2011 Awarepoint Corporation announced ... at the First Annual Digital Healthcare Innovation Summit ... Intercontinental New York Barclay in New York. Joining Deady on ... of Dell Healthcare Services and Kaveh Safavi, M.D., vice president ...
Cached Medicine Technology:Boston Scientific Announces Its ACC 2011 Schedule 2Boston Scientific Announces Its ACC 2011 Schedule 3Boston Scientific Announces Its ACC 2011 Schedule 4Boston Scientific Announces Its ACC 2011 Schedule 5Boston Scientific Announces Its ACC 2011 Schedule 6Awarepoint CEO Jay Deady to Serve as Panelist at IBF's Digital Healthcare Innovation Summit 2Awarepoint CEO Jay Deady to Serve as Panelist at IBF's Digital Healthcare Innovation Summit 3
(Date:3/2/2015)... March 02, 2015 Four Seasons Resort Maui ... its 25th anniversary this year, having officially opened its doors ... luxury resort is honoring over 70 employees who started on ... from amongst the approximately 400 original employees. The celebration ... Oceanfront Lawn. , This Four Seasons flagship resort, ...
(Date:3/2/2015)... 02, 2015 In light of the ... Xarelto (rivaroxaban) tablets, Ford & Associates Nationwide ... helpful for future users, but may come too late ... taking the drug. The FDA has now included the ... Reactions on Xarelto's label. The term “cytolytic hepatitis” has ...
(Date:3/2/2015)... March 02, 2015 Many mainstream media ... cases of measles. But how much of that news ... their toddlers to prevent measles, but whose youngsters later ... lectures from 150 speakers comprised of professionals, clinicians, researchers, ... recent news stories and questions about the body and ...
(Date:3/2/2015)... California (PRWEB) March 02, 2015 Final ... of the TranStatic Volume 2 from Pixel Film Studios. , ... made exclusively for FCPX,” said Christina Austin, CEO of Pixel ... have in any Final Cut Pro X editors toolbox.” , ... to the next with media altering static scrambling effects from ...
(Date:3/1/2015)... 2015 Security Life Insurance Company ... market, announced the addition of stand-alone individual vision ... Insurance launched today, complete with two plan options. ... the VSP® Vision Care network encompassing a strong ... space. The PrimeStar Select Vision plan will use ...
Breaking Medicine News(10 mins):Health News:Celebrating Four Seasons Resort Maui’s 25th Anniversary 2Health News:Ford & Associates Nationwide Legal Services, A.P.C., Comments on Xarelto Lawsuits Upon FDA Revisions 2Health News:Ford & Associates Nationwide Legal Services, A.P.C., Comments on Xarelto Lawsuits Upon FDA Revisions 3Health News:Ford & Associates Nationwide Legal Services, A.P.C., Comments on Xarelto Lawsuits Upon FDA Revisions 4Health News:Growing List of Professionals Gather for World’s Most Comprehensive Autism Conference in Chicago, May 2015 2Health News:Pixel Film Studios released the TranStatic Volume 2 plugin for Final Cut Pro X today 2Health News:Security Life Insurance Company Launches Individual Vision Insurance Product 2
... PAUL, Minn., Jan. 29 U.S. President Barack ... on human embryonic stem cells (hESC) research and is ... the issue. On Aug. 9, 2001, the Bush administration ... those hESC lines derived before that date. Jonathan ...
... have complications, without ill effects, study finds , , THURSDAY, Jan. ... to babies still in the womb can reduce their post-birth ... growth the way multiple courses can, new research shows. , ... those given a second dose of steroids in utero had ...
... PRO Educational Initiative are AnnouncedPITTSBURGH, Jan. 29 ... electronic patient reported outcomes (ePRO) solutions and ... opened registration for ePROficiency(TM) 2009 -- its ... research professionals can visit http://www.invivodata.com/epro2009 ...
... American businesses take belt-,tightening to new levels to ... a new service to help organizations address one ... EquivaMeds ( www.EquivaMeds.com ) helps self-insured ... helps members analyze their,current medications, identify lower cost ...
... interventions developed by UCSF researchers have been selected ... and Prevention,s 2008 Compendium of Evidence-based HIV Prevention ... Video Doctor and the Healthy Living Projectcomprise two ... 57 rigorously evaluated highly effective HIV prevention programs ...
... BTA stat(R) Test Detects Bladder Tumor Associated Antigen in UrineCORTLANDT ... announce the direct availability of the BTA stat (R) ... (R) test is a point of care technology for the ... antibodies to detect the presence of bladder tumor associated antigen ...
Cached Medicine News:Health News:University of Minnesota's Internationally Recognized Stem Cell Experts Available for Interviews on What Lifting the Federal Funding Restrictions Will Mean to Stem Cell Research and to Patients Who Stand to Benefit 2Health News:Additional Steroid Dose May Help Preemies 2Health News:Additional Steroid Dose May Help Preemies 3Health News:invivodata Opens Registration for Annual Patient Reported Outcomes Conference 2Health News:invivodata Opens Registration for Annual Patient Reported Outcomes Conference 3Health News:CDC recognizes UCSF's research as critical to HIV prevention 2Health News:CDC recognizes UCSF's research as critical to HIV prevention 3Health News:Polymedco Introduces Point of Care Test for Recurrent Bladder Cancer Detection 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: